Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

NCT05252429 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Effect of Drug

Interventions

DRUG: Docetaxel
DRUG: Pembrolizumab

Sponsor

Hokkaido University Hospital

Collaborators

[object Object]